Fig. 2

Comparison of the phenotype and components of eHD-NKs and eAML-NKs. A Phase contrast images of HD-NKs and AML-NKs at the indicated time points (day 0, 7, 14) during the 14-days’ in vitro amplification and activation. Scale bar = 100 μm. B Fold change of NK cells in the HD-NKs and AML-NKs groups. C, D Representative FCM diagrams of total (CD3⁻CD56⁺) NK cells in expanded NK cells (eHD-NKs, eAML-NKs) (C) and statistical analysis (D) of total (CD3⁻CD56⁺) NK cells in resident NK cells (rHD-NKs, rAML-NKs) and expanded NK cells (eHD-NKs, eAML-NKs). E, F FCM diagrams (E) and statistical analysis (F) of total activated NK cells (CD3⁻CD56⁺CD16⁺) and the subsets (NKG2D⁺, CD25⁺, NKp44⁺, NKp46⁺) in the indicated groups. All data were shown as mean ± SEM (N = 3 independent experiments). *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; NS: not significant